Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Financing Activities (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Cash from Financing Activities for 5 consecutive years, with $66.6 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities changed N/A year-over-year to $66.6 million; the TTM value through Mar 2026 reached $66.4 million, down 61.62%, while the annual FY2025 figure was -$288000.0, 100.16% down from the prior year.
  • Cash from Financing Activities hit $66.6 million in Q1 2026 for Phathom Pharmaceuticals, up from -$97000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $212.0 million in Q4 2023 and bottomed at -$271000.0 in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $49.3 million, with a median of $24.6 million recorded in 2022.
  • Year-over-year, Cash from Financing Activities skyrocketed 938800.0% in 2024 and then crashed 100.37% in 2025.
  • Phathom Pharmaceuticals' Cash from Financing Activities stood at $24.6 million in 2022, then skyrocketed by 761.9% to $212.0 million in 2023, then tumbled by 87.71% to $26.0 million in 2024, then plummeted by 100.37% to -$97000.0 in 2025, then surged by 68801.03% to $66.6 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $66.6 million, -$97000.0, and -$271000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.